Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease

Clinical and Experimental Immunology

Volumn 139, Issue 3, 2005, Pages 575-579

  Takeshita, Seiichiro ^a   Kawamura, Y ^b   Takabayashi, H ^a   Yoshida, N ^a   Nonoyama, S ^b  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Coronary artery lesions; Endostatin; Endothelial cells; Kawasaki disease; Vascular endothelial growth factor

Indexed keywords

ACETYLSALICYLIC ACID; ENDOSTATIN; IMMUNOGLOBULIN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE CONTROL; ENDOTHELIUM CELL; FEMALE; FEVER; HUMAN; HUMAN CELL; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ACUTE DISEASE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CORONARY DISEASE; ECHOCARDIOGRAPHY; ENDOSTATINS; FEMALE; FEVER; HUMANS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RISK; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 14744297361     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02714.x     Document Type: Article

References (30)

1. Cines DB, Pollak ES, Buck CA et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91:3527-61.
2. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. MoI Biol Cell 1992; 3:211-20.
3. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-9.
4. O'Reilly MS, Boehm T et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-85.
5. Yamaguchi N, Anand-Apte B, Lee M et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999; 18:4414-23.
6. Feldman AL, Pak H, Yang JC, Alexander HR Jr, Libutti SK. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 2001; 91:1525-9.
7. Feldman AL, Alexander HR Jr, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 2002; 95:1637-43.
8. Zhao J, Yan F, Ju H, Tang J, Qin J. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 2004; 204:87-95.
9. Bono P, Teerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 2003; 97:2767-75.
10. Nagashima M, Asano G, Yoshino S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol 2000; 27:2339-42.
11. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneus lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54:271-6.
12. Kato H, Koike S, Yamamoto M, Ito Y, Yano E. Coronary aneurysms in infants and young children with acute febrile mucocutaneus lymph node syndrome. J Pediatr 1975; 86:892-8.
13. Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989; 2:1298-302.
14. Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, Rowley AH. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 2002; 105:766-9.
15. Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 2003; 23:576-81.
16. Suzuki A, Miyagawa-Tomita S, Komatsu K, Nishikawa T, Sakomura Y, Horie T, Nakazawa M. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease: immunohistochemical study. Circulation 2000; 101:2935-41.
17. Terai M, Yasukawa K, Narumoto S, Tateno S, Oana S, Kohno Y. Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol 1999; 83:337-9.
18. Ohno T, Yuge T, Kariyazono H, Igarashi H, Joh-oK, Kinugawa N, Kusuhara K, Hara T. Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 2002; 161:105-11.
19. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22.
20. Hamamichi Y, Ichida F, Yu X et al. Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: its possible role in progression of coronary artery lesions. Pediatr Res 2001; 49:74-80.
21. Hirose S, Hamashima Y. Morphological observations on the vasculitis in the mucocutaneous lymph node syndrome. A skin biopsy study of 27 patients. Eur J Pediatr 1978; 129:17-27.
22. Leung DY, Geha RS, Newburger JW, Burns JC, Fiers W, Lapierre LA, Pober JS. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med 1986; 164:1958-72.
23. Asahara T, Takahashi T, Masuda H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 18:3964-72.
24. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Tokutomi T, Sekine I. Circulating endothelial cells in Kawasaki disease. Clin Exp Immunol 2003; 131:536-40.
25. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Sukhatme VP. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274:11721-6.
26. Kranenburg O, Kroon-Batenburg LM, Reijerkerk A, Wu YP, Voest EE, Gebbink MF. Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. FEES Lett 2003; 539:149-55.
27. Seko Y, Fukuda S, Nagai R. Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy. Clin Sci (Lond) 2004; 106:439-42.
28. Gora-Tybor J, Blonski JZ, Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Med Inflamm 2003; 12:167-71.
29. Funatsu H, Yamashita H, Noma H, Mochizuki H, Mimura T, Ikeda T, Hori S. Outcome of vitreous surgery and the balance between vascular endothelial growth factor and endostatin. Invest Ophthalmol Vis Sci 2003; 44:1042-7.
30. Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y, March KL. Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease. J Am Coll Cardiol 2004; 43:1383-7.